Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment

BACKGROUND: Emerging data suggest that patients with enzalutamide-treated prostate cancer with increased programmed death-ligand 1 (PD-L1) expression may benefit from anti-PD-L1 treatment. Unfortunately, the Phase III IMbassador250 clinical trial revealed that the combination of atezolizumab (a PD-L...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Pengfei, Yang, Joy C, Chen, Bo, Nip, Christopher, Van Dyke, Jonathan E, Zhang, Xiong, Chen, Hong-Wu, Evans, Christopher P, Murphy, William J, Liu, Chengfei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163595/
https://www.ncbi.nlm.nih.gov/pubmed/37147019
http://dx.doi.org/10.1136/jitc-2022-006581

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163595/
https://www.ncbi.nlm.nih.gov/pubmed/37147019
http://dx.doi.org/10.1136/jitc-2022-006581

Ejemplares similares